Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant

Vaccine

Volumn 25, Issue 41, 2007, Pages 7168-7176

  Chaitra, M G ^a   Nayak, R ^a   Shaila, M S ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Mycobacterium tuberculosis; PE PPE proteins; T cell antigens

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; RECOMBINANT PROTEIN; RV1818C PROTEIN; RV3018C PROTEIN; RV3812 PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FEMALE; GENE; IMMUNE RESPONSE; IMMUNITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RV1818C GENE; RV3018C GENE; RV3812 GENE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CELL WALL SKELETON; CORD FACTORS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FREUND'S ADJUVANT; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LIPID A; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 34648814055     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.026     Document Type: Article

References (34)

1. Arachi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72 (1991) 1-6
2. Bloom B.R., and Murray C.J.L. Tuberculosis: commentary on a re-emergent killer. Science 257 (1992) 1055-1064
3. Bloom B.R., and Mckinney J.D. The death and resurrection of tuberculosis. Nat Med 5 (1999) 872-874
4. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 89 (1992) 12013-12017
5. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30 (2000) 3689-3698
6. Huygen K.J., Content O., Denis D.L., Montgomery A.M., Yawman R.R., and Deck C.M. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 (1996) 893-898
7. Lozes E., Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15 (1997) 830-833
8. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 (1999) 1702-1707
9. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
10. Espitia C., Laclette J.P., Mondragon-Palomino M., Amador A., Campuzano J., Martens A., et al. The PE-PGRS glycine-rich proteins of Mycobacterium tuberculosis: a new family of fibronectin-binding proteins?. Microbiology 145 (1999) 3487-3495
11. Banu S., Honore N., Saint-Joanis B., Philpott D., Prevost M.C., and Cole S.T. Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens?. Mol Microbiol 44 (2002) 9-19
12. Delogu G., Pusceddu C., Bua A., Fadda G., Brennan M.J., and Zanetti S. Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure. Mol Microbiol 52 (2004) 725-733
13. Brennan M.J., Delogu G., Chen Y., Bardarov S., Kriakov J., Alavi M., et al. Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells. Infect Immun 69 (2001) 7326-7333
14. Rachman H., Strong M., Ulrichs T., Grode L., Schuchhardt J., Mollenkopf H., et al. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect Immun 74 (2006) 1233-1242
15. Delogu G., and Brennan M.J. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun 69 (2001) 5606-5611
16. Camacho L.R., Ensergueix D., Perez E., Gicquel B., and Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 34 (1999) 257-267
17. Ramakrishnan L., Federspiel N.A., and Falkow S. Granuloma-expression of mycobacterium virulence proteins from PE-PGRS family. Science 288 (2000) 1436-1439
18. Tekaia F., Gordon S.V., Garnier T., Brosch R., Barrell B.G., and Cole S.T. Analysis of the proteome of Mycobacterium tuberculosis in silico. Tuberc Lung Dis 79 (1999) 329-342
19. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2-binding peptides based on independent binding of individual peptide side-chains. J Immunol 152 (1994) 163-175
20. Chaitra M.G., Hariharaputran S., Chandra N.R., Shaila M.S., and Nayak R. Defining putative T cell epitopes from PE and PPE families of proteins of Mycobacterium tuberculosis with vaccine potential. Vaccine 23 (2005) 1265-1272
21. Grun J.L., Maurer P.H., and Different T. helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121 (1989) 134-145
22. Holten-Andersen L., Doherty T.M., Korsholm K.S., and Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72 (2004) 1608-1617
23. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65 (1997) 623-629
24. Watanabe R., Yoo Y.C., Hata K., Mitobe M., Koike Y., Nishizawa M., et al. Inhibitory effect of trehalose dimycolate:TDM; and its stereoisometric derivatives, trehalose dicorynomycolates:TDCMs, with low toxicity on lung metastasis of tumour cells in mice. Vaccine 17 (1999) 1484-1492
25. Razeghifard M.R. On-column refolding of recombinant human interleukin-4 from inclusion bodies. Protein Exp Purif 37 (2004) 180-186
26. Mullerad J., Michal I., Fishman Y., Hovav A., Barletta R.G., and Bercovier H. The immunogenicity of Mycobacterium paratuberculosis 85B antigen. Med Microbiol Immunol 190 (2002) 179-187
27. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., and Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 94 (1997) 5243-5248
28. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334 (1988) 255-258
29. Dunachie S.J., and Hill A.V.S. Prime-boost strategies for malaria vaccine development. J Exp Biol 206 (2003) 3771-3779
30. Jurado A., Carballido J., Griffel H., Hochkeppel H.K., and Wetzel G.D. The immunomodulatory effects of interferon-gamma on mature B lymphocyte responses. Experientia 45 (1989) 521-526
31. + T cells requires the production of gamma interferon. Infect Immun 66 (1998) 830-834
32. + T cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb84. Vaccine 22 (2004) 1964-1972
33. + T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol 162 (1999) 5407-5416
34. Mullerad J., Hovav A.H., Fishman Y., Barletta R.G., and Bercovier H. Antigenicity of Mycobacterium paratuberculosis superoxide dismutase in mice. FEMS Immunol Med Microbiol 34 (2002) 81-88